Research

Research & Clinical Studies

Tulsa Retina Consultants is pleased to announce we are now enrolling patients in clinical studies. As always our goal is to continuously strive to raise the bar in all aspects of patient-centered retina care.

By hosting and conducting clinical studies right here in Tulsa, while focusing on the latest retina research, our goal is to provide opportunities for our patients to become active participants in research which may prove beneficial to many who suffer from various retinal problems world-wide.

Follow us for more information on upcoming clinical studies regarding retinal diseases such as:

  • Diabetic Retinopathy
  • Macular Degeneration
  • Diabetic Macular Edema
  • Retinal Vein Occlusion

Ocutrix Vision Technologies has sucessfully completed the first pre-pilot trial for the technology.

The study was conducted here at Tulsa Retina Consultants and assisted by Scott Hewitt, CCRC and Deborah Hardison, COMT.

Subjects had difficulty reading and most had not been able to read for years due to Advanced Macular Degeneration (AMD). Using the Oculenz headset all subjects were able to read 30-point type at a standard reading pace, with some reading down to 12-point type. These results suggest that the brain is able to adapt to the view presented by Oculenz and comprehend the entire modified view all the while ignoring the blind spot (scotoma) caused by AMD. 

Oculenz accomplishes this by first detecting a subject's blind spot and then moving words and letters from this sightless area into areas of the retina where the subject can see and perceive them.

"This is a ground-breaking study," said Dr. Thomas A. Finley, MD, of Tulsa Retina Consultants, and chairman of the Ocutrix Medical Advirsory board. "The Oculenz headset was a significant aid for improving functional vision."

Read more here: https://www.mddionline.com/ocutrx-harnesses-power-ar-vision-correction